Short Interest in AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Drops By 40.8%

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) saw a large drop in short interest in July. As of July 31st, there was short interest totaling 913,892 shares, a drop of 40.8% from the July 15th total of 1,543,826 shares. Based on an average daily volume of 741,607 shares, the days-to-cover ratio is presently 1.2 days. Currently, 6.3% of the shares of the company are sold short.

AIM ImmunoTech Trading Up 6.5%

NYSEAMERICAN AIM traded up $0.02 on Wednesday, reaching $0.25. The company’s stock had a trading volume of 809,352 shares, compared to its average volume of 12,918,796. AIM ImmunoTech has a 52 week low of $0.19 and a 52 week high of $2.98. The firm has a market cap of $7.58 million, a PE ratio of -0.08 and a beta of 1.20. The business has a 50-day moving average price of $0.30 and a 200 day moving average price of $0.55.

AIM ImmunoTech (NYSEAMERICAN:AIM) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.43) EPS for the quarter. The business had revenue of $0.03 million for the quarter. Analysts anticipate that AIM ImmunoTech will post -0.63 earnings per share for the current fiscal year.

Hedge Funds Weigh In On AIM ImmunoTech

A hedge fund recently raised its stake in AIM ImmunoTech stock. DRW Securities LLC boosted its stake in AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) by 60.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,545 shares of the company’s stock after buying an additional 26,254 shares during the quarter. DRW Securities LLC owned approximately 2.12% of AIM ImmunoTech worth $79,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 12.02% of the company’s stock.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets cut their target price on AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $9.00.

About AIM ImmunoTech

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.